CLAIMS

1. A product comprising an oral pharmaceutical formulation of L-ornithine phenylacetate in a daily dosage of 8 g to 15 g.

2. The product of Claim 1, wherein the daily dosage of L-ornithine phenylacetate is 8 g to 12 g.

3. The product of Claim 1 or 2, wherein the daily dosage of L-ornithine phenylacetate is in a single unit dosage form.

4. The product of Claim 1 or 2, wherein the daily dosage of L-ornithine phenylacetate is in two or more unit dosage forms.

5. The product of any one of Claims 3 or 4, wherein the unit dosage form is a tablet, a capsule, a pill, pellets, free-flowing powder, or liquid.

6. The product of any one of Claims 1 to 5, wherein the oral pharmaceutical formulation provides an immediate release profile of L-ornithine phenylacetate upon oral administration.

7. Use of an oral pharmaceutical formulation of L-ornithine phenylacetate in the preparation of a medicament for treating or ameliorating hyperammonemia in a subject, wherein the medicament comprises a daily dose of 8 g to 15 g L-ornithine phenylacetate.

8. The use of Claim 7, wherein the medicament comprises a daily dose of 8 g to 12 g L-ornithine phenylacetate.

9. The use of Claim 7 or 8, wherein said oral pharmaceutical formulation provides a plasma Cmax of phenylacetic acid from 10 μg/mL to 120 μg/mL.

10. The use of any one of Claims 7 to 9, wherein said oral pharmaceutical formulation provides a plasma Cmax of phenylacetylglutamine from 10 μg/mL to 80 μg/mL.

11. Use of an oral pharmaceutical formulation comprising L-ornithine phenylacetate in the preparation of a medicament for treating or ameliorating hyperammonemia in a subject, wherein the medicament comprises a daily dose of 8 g to 15 g L-ornithine phenylacetate, and provides a plasma Cmax of phenylacetic acid ranging from 10 μg/mL to 150 μg/mL.

12. The use of Claim 11, wherein the medicament comprises a daily dose of 8 g to 12 g L-ornithine phenylacetate.

13. The use of Claim 11 or 12, wherein the plasma Cmax level of phenylacetic acid is from 40 μg/mL to 120 μg/mL.

14. The use of any one of Claims 11 to 13, wherein the medicament provides a plasma Cmax of phenylacetylglutamine ranging from 5 μg/mL to 100 μg/mL.

15. The use of Claim 14, wherein the plasma Cmax of phenylacetylglutamine is from 25 μg/mL to 50 μg/mL.

16. Use of an oral pharmaceutical formulation comprising L-ornithine phenylacetate in the preparation of a medicament for treating or ameliorating hyperammonemia in a subject, wherein the medicament comprises a daily dose of 8 g to 15 g L-ornithine phenylacetate, and provides a plasma AUC_{0-t} or AUC_{0-inf} of phenylacetic acid ranging from 100 hr*μg/mL to 1000 hr*μg/mL.

17. The use of Claim 16, wherein the medicament comprises a daily dose of 8 g to 12 g L-ornithine phenylacetate.

18. The use of Claim 16 or 17, wherein the plasma AUC_{0-t} or AUC_{0-inf} of phenylacetic acid is from 400 hr*μg/mL to 550 hr*μg/mL.

19. The use of any one of Claims 16 to 18, wherein the plasma AUC_{0-t} or AUC_{0-inf} of phenylacetylglutamine is from 25 hr*μg/mL to 500 hr*μg/mL.

20. The use of Claim 19, wherein the plasma AUC_{0-t} of phenylacetylglutamine is from 120 hr*μg/mL to 180 hr*μg/mL.

21. The use of Claim 19, wherein the plasma AUC_{0-inf} of phenylacetylglutamine is from 150 hr*μg/mL to 200 hr*μg/mL.

22. The use of any one of Claims 7 to 21, wherein the subject has acute liver failure or chronic liver disease.

23. The use of Claim 22, wherein the subject has liver cirrhosis or liver decompensation, and wherein the liver cirrhosis has a classification of Child-Pugh class A, B or C.

24. The use of any one of Claims 7 to 21, wherein the subject has one or more conditions selected from the group consisting of hepatic encephalopathy, portal hypertension, and urea cycle disorder.

25. The use of any one of Claims 7 to 24, wherein the oral pharmaceutical formulation provides an immediate release of L-ornithine phenylacetate.

26. The use of any one of Claims 7 to 25, wherein the medicament is for administration once a day.

27. The use of any one of Claims 7 to 25, wherein the medicament is for administration two or more times a day.

28. The use of Claim 27, wherein the medicament is for administration two times a day, each time comprising 4 g to 6 g of L-ornithine phenylacetate.

29. The use of Claim 28, wherein the 4 g to 6 g of L-ornithine phenylacetate is in a single unit dosage form.

30. The use of Claim 28, wherein the 4 g to 6 g of L-ornithine phenylacetate is in two or more unit dosage forms.

31. The use of Claim 30, wherein the 4 g to 6 g L-ornithine phenylacetate is in 4 to 6 unit dosage forms each comprising 1 g L-ornithine phenylacetate.

32. The use of any one of Claims 7 to 31, wherein said oral pharmaceutical formulation provides conversion of phenylacetate to phenylacetylglutamine of greater than 50% over 24 hours.

33. The use of any one of Claims 7 to 32, wherein said oral pharmaceutical formulation provides conversion of phenylacetate to phenylacetylglutamine of greater than 80% over 24 hours.

34. The use of any one of Claims 7 to 33, wherein the medicament is for administration with food.